Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 4/2014

01.12.2014 | short review

Gene signature profiling of gynaecological malignancies

verfasst von: Peter Horak, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Genetic profiling of cancer may lead to a better understanding of its intra- as well as intertumoural heterogeneity as well as targeted, patient-oriented cancer therapy. Due to the recent advances in molecular biology, important steps towards this goal have been accomplished. Among others, several large profiling analyses of gynaecologic malignancies have been completed and published recently. Most notably, these comprehensive molecular analyses expose a high degree of cancer complexity and heterogeneity. Integration of this data into clinical practice will result in new tumour classifications and possibly change our understanding of cancer pathogenesis and thus necessitate the development of novel diagnostic and therapeutic algorithms.
Literatur
1.
Zurück zum Zitat Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317–23. doi:10.1200/JCO.2013.52.4298.CrossRef Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians’ attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014;32(13):1317–23. doi:10.1200/JCO.2013.52.4298.CrossRef
2.
Zurück zum Zitat Gampenrieder S, Rinnerthaler G, Greil R. Multi-gene signatures in breast cancer: actual clinical impact. Memo. 2014;7(1):16–21.CrossRef Gampenrieder S, Rinnerthaler G, Greil R. Multi-gene signatures in breast cancer: actual clinical impact. Memo. 2014;7(1):16–21.CrossRef
3.
Zurück zum Zitat Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2008;61(2):69–90. doi:10.3322/caac.20107.CrossRef Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2008;61(2):69–90. doi:10.3322/caac.20107.CrossRef
4.
Zurück zum Zitat Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28. doi:10.1038/nrc2644.PubMedCentralPubMedCrossRef Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415–28. doi:10.1038/nrc2644.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65(22):10602–12. doi:10.1158/0008-5472.CAN-05-2240.PubMedCrossRef Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005;65(22):10602–12. doi:10.1158/0008-5472.CAN-05-2240.PubMedCrossRef
6.
Zurück zum Zitat Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30. doi:10.1158/1078-0432.CCR-05-0508.PubMedCrossRef Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30. doi:10.1158/1078-0432.CCR-05-0508.PubMedCrossRef
7.
8.
Zurück zum Zitat Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109(10):3921–6. doi:10.1073/pnas.1117135109.PubMedCentralPubMedCrossRef Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109(10):3921–6. doi:10.1073/pnas.1117135109.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117(3):429–39. doi:10.1016/j.ygyno.2010.01.048.PubMedCentralPubMedCrossRef Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010;117(3):429–39. doi:10.1016/j.ygyno.2010.01.048.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008;5(10):577–87. doi:10.1038/ncponc1178.PubMedCrossRef Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008;5(10):577–87. doi:10.1038/ncponc1178.PubMedCrossRef
11.
Zurück zum Zitat Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880–4. doi:10.1038/ng.666.PubMedCentralPubMedCrossRef Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880–4. doi:10.1038/ng.666.PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. doi:nature10166.CrossRef TCGA. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. doi:nature10166.CrossRef
13.
Zurück zum Zitat Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517–25.PubMedCentralPubMed Verhaak RG, Tamayo P, Yang JY, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123(1):517–25.PubMedCentralPubMed
14.
Zurück zum Zitat Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi33–8. doi:10.1093/annonc/mdt353. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl. 6):vi33–8. doi:10.1093/annonc/mdt353.
15.
16.
Zurück zum Zitat Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.PubMedCrossRef Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.PubMedCrossRef
17.
Zurück zum Zitat Huang L, Zheng M, Zhou QM, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117(15):3363–73. doi:10.1002/cncr.25870.PubMedCrossRef Huang L, Zheng M, Zhou QM, et al. Identification of a gene-expression signature for predicting lymph node metastasis in patients with early stage cervical carcinoma. Cancer. 2011;117(15):3363–73. doi:10.1002/cncr.25870.PubMedCrossRef
18.
Zurück zum Zitat Martin CM, Astbury K, McEvoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–59. doi:10.1007/978-1-59745-447-6_15.PubMedCrossRef Martin CM, Astbury K, McEvoy L, et al. Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy. Methods Mol Biol. 2009;511:333–59. doi:10.1007/978-1-59745-447-6_15.PubMedCrossRef
19.
Zurück zum Zitat Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331(2):269–91. doi:10.1016/j.virol.2004.09.045.PubMedCrossRef Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy. Virology. 2005;331(2):269–91. doi:10.1016/j.virol.2004.09.045.PubMedCrossRef
20.
Zurück zum Zitat Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–9.PubMedCentralPubMedCrossRef Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009;112(2):293–9.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006;12(19):5632–40. doi:10.1158/1078-0432.CCR-06-0357.PubMedCrossRef Bachtiary B, Boutros PC, Pintilie M, et al. Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin Cancer Res. 2006;12(19):5632–40. doi:10.1158/1078-0432.CCR-06-0357.PubMedCrossRef
22.
Zurück zum Zitat Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191–6. doi:10.1038/nature08658.PubMedCentralPubMedCrossRef Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature. 2010;463(7278):191–6. doi:10.1038/nature08658.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. doi:10.1038/nature12477. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. doi:10.1038/nature12477.
25.
Zurück zum Zitat Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol. 2014;11(2):109–18. doi:10.1038/nrclinonc.2013.244.PubMedCrossRef Shrager J, Tenenbaum JM. Rapid learning for precision oncology. Nat Rev Clin Oncol. 2014;11(2):109–18. doi:10.1038/nrclinonc.2013.244.PubMedCrossRef
Metadaten
Titel
Gene signature profiling of gynaecological malignancies
verfasst von
Peter Horak, MD, PhD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0177-1

Weitere Artikel der Ausgabe 4/2014

memo - Magazine of European Medical Oncology 4/2014 Zur Ausgabe